Ivan Candido-Ferreira

Ivan Candido-Ferreira

Auto-generated profile, based on publicly available information

Ivan Candido-Ferreira

University of Oxford

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Developmental Cell
Verified
Journal Article
Open access
RWRuth M. Williams
Ruth M. Williams
ICIvan Candido-Ferreira
Ivan Candido-Ferreira
EREmmanouela Repapi
Emmanouela Repapi
DGDaria Gavriouchkina
Daria Gavriouchkina
USUpeka Senanayake
Upeka Senanayake
TSTatjana Sauka-Spengler
Tatjana Sauka-Spengler
Precise control of developmental processes is encoded in the genome in the form of gene regulatory networks (GRNs). Such multi-factorial systems are difficult to decode in vertebrates owing to their complex gene hierarchies and dynamic molecular interactions. Here we present a genome-wide in vivo reconstruction of the GRN underlying development of the multipotent neural crest (NC) embryonic cell population. By coupling NC-specific epigenomic and transcriptional profiling at population and single-cell levels with genome/epigenome engineering in vivo, we identify multiple regulatory layers governing NC ontogeny, including NC-specific enhancers and super-enhancers, novel trans-factors, and cis-signatures allowing reverse engineering of the NC-GRN at unprecedented resolution. Furthermore, identification and dissection of divergent upstream combinatorial regulatory codes has afforded new insights into opposing gene circuits that define canonical and neural NC fates early during NC ontogeny. Our integrated approach, allowing dissection of cell-type-specific regulatory circuits in vivo, has broad implications for GRN discovery and investigation.

1 January 2012 in Frontiers in Microbiology
Verified
Journal Article
Open access
GAGabriela Ayroza
Gabriela Ayroza
IFIvan L. C. Ferreira
Ivan L. C. Ferreira
RSRaphael S. R. Sayegh
Raphael S. R. Sayegh
ATAlexandre Keiji Tashima
Alexandre Keiji Tashima
PJPedro Ismael Silva Junior
Pedro Ismael Silva Junior
The aim of this study was to screen the venom of the theraposid spider Avicularia juruensis for the identification of antimicrobial peptides (AMPs) which could be further used as prototypes for drug development. Eleven AMPs, named juruentoxins, with molecular weight ranging from 3.5 to 4.5 kDa, were identified by mass spectrometry after the soluble venom was separated by high performance liquid chromatography. Juruentoxins have a putative inhibitory cystine knot (ICK) motif, generally found in neurotoxins, which are also resistant to proteolysis. One juruentoxin that has 38 amino acid residues and three disulfide bonds were characterized, to which we proposed the name Juruin. Based on liquid growth inhibition assays, it has potent antifungal activity in the micromolar range. Importantly, Juruin lacks haemolytic activity on human erythrocytes at the antimicrobial concentrations. Based on the amino acid sequence, it is highly identical to the insecticidal peptides from the theraposid spiders Selenocosmia huwena, Chilobrachys jingzhao, and Haplopelma schmidti from China, indicating they belong to a group of conserved toxins which are likely to inhibit voltage-gated ion channels. Juruin is a cationic AMP, and Lys22 and Lys23 show maximum positive charge localization that might be important for receptor recognition. Although it shows marked sequence similarity to neurotoxic peptides, Juruin is a novel exciting molecule with potent antifungal activity, which could be used as a novel template for development of drugs against clinical resistant fungi strains.

11 May 2021 in medRxiv
Verified
Preprint
Open access
PDF file
DADavid J Ahern
David J Ahern
ZAZhichao Ai
Zhichao Ai
MAMark Ainsworth
Mark Ainsworth
CAChris Allan
Chris Allan
AAAlice Allcock
Alice Allcock
YZYasemin-Xiomara Zurke
Yasemin-Xiomara Zurke
Summary: Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete understanding of potentially druggable immune mediators of disease. To advance this, we present a comprehensive multi-omic blood atlas in patients with varying COVID-19 severity and compare with influenza, sepsis and healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity revealed cells, their inflammatory mediators and networks as potential therapeutic targets, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Tensor and matrix decomposition of the overall dataset revealed feature groupings linked with disease severity and specificity. Our systems-based integrative approach and blood atlas will inform future drug development, clinical trial design and personalised medicine approaches for COVID-19.

1 September 2020 in STAR Protocols
Verified
Journal Article
Open access
MLMartyna Lukoseviciute
Martyna Lukoseviciute
ILIrving T.C. Ling
Irving T.C. Ling
USUpeka Senanayake
Upeka Senanayake
ICIvan Candido-Ferreira
Ivan Candido-Ferreira
GTGunes Taylor
Gunes Taylor
TSTatjana Sauka-Spengler
Tatjana Sauka-Spengler
Chromatin immunoprecipitation with sequencing (ChIP-seq) has been instrumental in understanding transcription factor (TF) binding during gene regulation. ChIP-seq requires specific antibodies against desired TFs, which are not available for numerous species. Here, we describe a tissue-specific biotin ChIP-seq protocol for zebrafish and chicken embryos which utilizes AVI tagging of TFs, permitting their biotinylation by a co-expressed nuclear biotin ligase. Subsequently, biotinylated factors can be precipitated with streptavidin beads, enabling the user to construct TF genome-wide binding landscapes like conventional ChIP-seq methods.

9 January 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ICIvan Lavander Candido-Ferreira
Ivan Lavander Candido-Ferreira
TKThales Kronenberger
Thales Kronenberger
RSRaphael Santa Rosa Sayegh
Raphael Santa Rosa Sayegh
IBIsabel Batista
Isabel Batista
PJPedro Ismael Silva Junior
Pedro Ismael Silva Junior
The ubiquitin-proteasome pathway (UPP) is a hallmark of the eukaryotic cell. In jawed vertebrates, it has been co-opted by the adaptive immune system, where proteasomal degradation produces endogenous peptides for major histocompatibility complex (MHC) class I antigen presentation. However, proteolytic products are also necessary for the phylogenetically widespread innate immune system, as they often play a role as host defense peptides (HDPs), pivotal effectors against pathogens. Here, we report the identification of the arachnid HDP oligoventin, which shares homology to a core member of the UPP, E3 ubiquitin ligases. Oligoventin has broad antimicrobial activity and shows strong synergy with lysozymes. Using computational and phylogenetic approaches, we show high conservation of the oligoventin signature in HECT E3s. In silico simulation of HECT E3s self-proteolysis provides evidence that HDPs can be generated by fine-tuned 26S proteasomal degradation, and therefore are consistent with the hypothesis that oligoventin is a cryptic peptide released by the proteolytic processing of an Nedd4 E3 precursor protein. Finally, we compare the production of HDPs and endogenous antigens from orthologous HECT E3s by proteasomal degradation as a means of analysing the UPP coupling to metazoan immunity. Our results highlight the functional plasticity of the UPP in innate and adaptive immune systems as a possibly recurrent mechanism to generate functionally diverse peptides.

4 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RWRuth Williams
Ruth Williams
GTGunes Taylor
Gunes Taylor
ILIrving T C Ling
Irving T C Ling
ICIvan Candido-Ferreira
Ivan Candido-Ferreira
SMSarah Mayes
Sarah Mayes
TSTatjana Sauka-Spengler
Tatjana Sauka-Spengler
Neurocristopathies such as CHARGE syndrome result from aberrant neural crest development. A large proportion of CHARGE cases are attributed to mutations in the gene encoding CHD7, chromodomain helicase DNA binding protein 7, which remodels chromatin. While the role for CHD7 in neural crest development is well documented, it remains elusive how this seemingly ubiquitous factor is specifically upregulated in neural crest cells. Here, we use epigenomic profiling of chick neural crest to identify a cohort of enhancers regulating Chd7 expression in neural crest cells and other tissues. We functionally validate upstream transcription factor binding at candidate enhancers, revealing novel epistatic relationships between neural crest master regulators and Chd7. To our knowledge, this is the first report of tissue-specific regulation of a chromatin remodeller. Furthermore, we find conserved enhancer features in human embryonic epigenomic data and validate the activity of the human equivalent CHD7 enhancers in the chick embryo. Collectively our findings embed Chd7 in the neural crest gene regulatory network and offer potentially clinically relevant elements for interpreting CHARGE syndrome cases without causative allocation.